The verified answer
As of Aug 2026, DEPLOY verifies NeuroLutions: 1 model. 1 source back the record.
CategoryBiometric wearables
Overview
NeuroLutions (now merged into Kandu, Inc.) developed the IpsiHand System, the first FDA-cleared brain-computer interface device for stroke rehabilitation. The wearable BCI translates brain signals from the uninjured hemisphere into hand movement. In 2024, CMS created a dedicated Medicare reimbursement code — the first for any BCI device. Merged with Kandu Health in 2025 with 0M financing.
Verified record
- Verified deployments
- None on file
- Active incidents
- None on file
Key facts
Data & sources
Web sources
1
1 source backing this record.View all →
Models (1)
View all models →NeuroLutions on the deployment map
View the global mapNeuroLutions has no verified deployments on the DEPLOY registry yet. Explore the deployment map by place and type.
No verified deployments for NeuroLutions on the DEPLOY record yet. Track NeuroLutions to know the moment the first one is verified.
Current leadership (2)
- Leo Petrossian CEOsecondary-verified
- Eric Leuthardt Co-founder & Chief Scientific Officersecondary-verified
Safety record
No incidents on record for NeuroLutions.
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Full safety record: incidents, sourcing, and exposure data →
Recent coverage
NeuroLutions in third-party press
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Record createdAug 8, 2026
Added to the verified registry
Sources (1)
Common questions
What is NeuroLutions?
What does NeuroLutions make?
Who is the CEO of NeuroLutions?
Where is NeuroLutions headquartered?
Where does NeuroLutions operate robots?
Is NeuroLutions a top robotics company?
When was NeuroLutions founded?
Is NeuroLutions safe?
Methodology: Verified · 1 source (no primary) · last reviewed 2026-08-08
Verification posture
Verified
Low confidence
Review state
Stable
Last reviewed 2026-08-08
Sources by quality tier
- 1
- unclassified
- Unclassified source
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for NeuroLutions.In the press
Recent coverage mentioning NeuroLutions from third-party publications. Automatically surfaced; not part of the verified registry record.
Kandu Health and Neurolutions Merge to Form Kandu, Inc.
NeuroLutions merged with Kandu Health with 0M financing led by Ally Bridge Group and AMED Ventures
NeuroLutions Receives FDA De Novo Market Authorization for IpsiHand
First FDA-authorized BCI for stroke rehab; IpsiHand translates brain signals from uninjured hemisphere into hand movement
Machine-readable surfaces
- Markdown mirror: /companies/neurolutions.md
- RSS feed: /companies/neurolutions/feed.xml
- JSON-LD: embedded in this page’s head
- REST API: /v1/companies/c5677c1a-8c95-438d-9619-849950504010
- Revision history: /companies/neurolutions/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Reality vs attention
NeuroLutions draws attention at the 18th percentile but verifies reality at the insufficient-data level among biometric robots.
Analysis
Limited public visibility and press coverage relative to peers.
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Aug 9, 2026